株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

創薬サービスの世界市場:プロセス、タイプ、薬剤タイプ、治療、企業別- 2025年までの予測

Drug Discovery Services Market by Process (Target Selection, Validation, Lead Optimization), Type (Medicinal Chemistry, DMPK), Drug Type (Biologics, Small Molecules), Therapeutic (Oncology, Neurology), Company (Tier 1, 2, 3) - Global Forecast to 2025

発行 MarketsandMarkets 商品コード 923896
出版日 ページ情報 英文 170 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.53円で換算しております。
創薬サービスの世界市場:プロセス、タイプ、薬剤タイプ、治療、企業別- 2025年までの予測 Drug Discovery Services Market by Process (Target Selection, Validation, Lead Optimization), Type (Medicinal Chemistry, DMPK), Drug Type (Biologics, Small Molecules), Therapeutic (Oncology, Neurology), Company (Tier 1, 2, 3) - Global Forecast to 2025
出版日: 2020年01月31日 ページ情報: 英文 170 Pages
概要

世界の創薬サービス市場は2020年の107億米ドルからCAGR12.1%で拡大し、2025年までに191億米ドルに達すると予測されています。同市場の成長は、医薬品、バイオ医薬品業界における研究開発費用の拡大、分析試験や治験サービスのアウトソーシングに対する需要拡大、奇病、オーファンドラッグの研究に対する取り組み、創薬への注力などの要素によるものです。また、途上国は市場に参入する企業にとって幅広い成長の機会を提供してくれるものと期待されています。

当レポートでは、世界の創薬サービス市場について調査し、セグメント別動向、2025年までの成長予測、地域別動向、および市場に参入する企業のプロファイルなどについてまとめています。

923896_4.1 DRUG DISCOVERY SERVICES MARKET OVERVIEW_FIGURE 12

第1章 イントロダクション

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 プレミアムインサイト

第5章 市場概要

  • イントロダクション
  • 市場動向
    • 促進因子
    • 阻害因子
    • 機会
    • 動向

第6章 創薬サービス市場:プロセス別

  • イントロダクション
  • 標的選定
  • 標的バリデーション
  • ヒットからのリード創製プロセスの特定
  • リード最適化
  • 候補バリデーション

第7章 創薬サービス市場:タイプ別

  • イントロダクション
  • 医科学サービス
  • 生物学サービス
  • 薬物代謝、薬物動態学

第8章 創薬サービス市場:薬剤タイプ別

  • イントロダクション
  • 低分子薬剤
  • 生物製剤

第9章 創薬サービス市場:治療分野別

  • イントロダクション
  • 腫瘍
  • 神経
  • 感染症、免疫系疾患
  • 消化系疾患
  • 心血管疾患
  • その他の治療分野

第10章 創薬サービス市場:企業タイプ別

  • イントロダクション
  • Tier 1
  • Tier 2
  • Tier 3

第11章 創薬サービス市場:地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋地域
  • その他の諸国

第12章 競合環境

  • 概要
  • 市場シェア分析
  • 競合シナリオ
  • 競合リーダーシップマッピング

第13章 企業プロファイル

第14章 付録

図表

LIST OF TABLES

  • TABLE 1 DRUG DISCOVERY PROCESS OVERVIEW
  • TABLE 2 RESEARCH PROJECTS FUNDED BY THE IRDIRC
  • TABLE 3 AVERAGE COST OF DRUGS APPROVED PER YEAR, 2004-2013
  • TABLE 4 DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2018-2025 (USD MILLION)
  • TABLE 5 DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 6 ADVANTAGES AND DISADVANTAGES OF SIRNA
  • TABLE 7 DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 8 DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 9 DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 10 DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 11 DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 12 MEDICINAL CHEMISTRY DRUG DISCOVERY SERVICES MARKET, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 13 BIOLOGY DRUG DISCOVERY SERVICES MARKET, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 14 DMPK DRUG DISCOVERY SERVICES MARKET, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 15 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
  • TABLE 16 DRUG DISCOVERY SERVICES MARKET FOR SMALL-MOLECULE DRUGS, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 17 DRUG DISCOVERY SERVICES MARKET FOR BIOLOGIC DRUGS, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 18 GLOBAL NUMBER OF CLINICAL TRIALS, BY THERAPEUTIC AREA (AS OF OCTOBER 2019)
  • TABLE 19 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 20 DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 21 DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGY, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 22 DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS AND IMMUNE SYSTEM DISEASES, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 23 DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 24 DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 25 DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 26 DRUG DISCOVERY SERVICES MARKET, BY COMPANY TYPE, 2018-2025 (USD MILLION) 72  
  • TABLE 27 DRUG DISCOVERY SERVICES MARKET FOR TIER 1 PHARMACEUTICAL COMPANIES, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 28 DRUG DISCOVERY SERVICES MARKET FOR TIER 2 PHARMACEUTICAL COMPANIES, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 29 DRUG DISCOVERY SERVICES MARKET FOR TIER 3 PHARMACEUTICAL COMPANIES, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 30 DRUG DISCOVERY SERVICES MARKET, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 31 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 32 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2018-2025 (USD MILLION)
  • TABLE 33 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 34 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
  • TABLE 35 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 36 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY COMPANY TYPE, 2018-2025 (USD MILLION)
  • TABLE 37 NUMBER OF CLINICAL TRIALS STARTED IN THE US, BY COMPANY, 2017
  • TABLE 38 US: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2018-2025 (USD MILLION)
  • TABLE 39 US: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 40 US: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
  • TABLE 41 US: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 42 NUMBER OF ACTIVE CLINICAL TRIALS IN CANADA, BY CONDITION (2019)
  • TABLE 43 NUMBER OF ACTIVE CLINICAL TRIALS IN CANADA, BY COMPANY, 2017
  • TABLE 44 CANADA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2018-2025 (USD MILLION)
  • TABLE 45 CANADA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 46 CANADA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
  • TABLE 47 CANADA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 48 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 49 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2018-2025 (USD MILLION)
  • TABLE 50 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 51 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
  • TABLE 52 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 53 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY COMPANY TYPE, 2018-2025 (USD MILLION) 87  
  • TABLE 54 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2018-2025 (USD MILLION)
  • TABLE 55 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 56 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
  • TABLE 57 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 58 UK: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2018-2025 (USD MILLION)
  • TABLE 59 UK: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 60 UK: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
  • TABLE 61 UK: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 62 NUMBER OF CLINICAL TRIALS STARTED IN FRANCE, BY COMPANY, 2017
  • TABLE 63 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2018-2025 (USD MILLION)
  • TABLE 64 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 65 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
  • TABLE 66 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 67 NUMBER OF CLINICAL TRIALS STARTED IN ITALY, BY COMPANY, 2017
  • TABLE 68 ITALY: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2018-2025 (USD MILLION)
  • TABLE 69 ITALY: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 70 ITALY: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
  • TABLE 71 ITALY: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 72 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2018-2025 (USD MILLION)
  • TABLE 73 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 74 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
  • TABLE 75 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 76 ROE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2018-2025 (USD MILLION)
  • TABLE 77 ROE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 78 ROE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
  • TABLE 79 ROE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 80 TOTAL NUMBER OF CLINICAL TRIALS IN APAC, BY THERAPEUTIC AREA, 2017 102  
  • TABLE 81 APAC: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 82 APAC: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2018-2025 (USD MILLION)
  • TABLE 83 APAC: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 84 APAC: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
  • TABLE 85 APAC: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 86 APAC: DRUG DISCOVERY SERVICES MARKET, BY COMPANY TYPE, 2018-2025 (USD MILLION)
  • TABLE 87 CHINA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2018-2025 (USD MILLION)
  • TABLE 88 CHINA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 89 CHINA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
  • TABLE 90 CHINA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 91 INDIA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2018-2025 (USD MILLION)
  • TABLE 92 INDIA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 93 INDIA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
  • TABLE 94 INDIA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 95 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2018-2025 (USD MILLION)
  • TABLE 96 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 97 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
  • TABLE 98 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 99 ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2018-2025 (USD MILLION)
  • TABLE 100 ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 101 ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
  • TABLE 102 ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 103 ROW: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2018-2025 (USD MILLION)
  • TABLE 104 ROW: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 105 ROW: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
  • TABLE 106 ROW: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION) 116  
  • TABLE 107 ROW: DRUG DISCOVERY SERVICES MARKET, BY COMPANY TYPE, 2018-2025 (USD MILLION)
  • TABLE 108 PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS (2017-2019)
  • TABLE 109 SERVICE LAUNCHES (2017-2019)
  • TABLE 110 MERGERS & ACQUISITIONS (2017-2019)
  • TABLE 111 EXPANSIONS (2017-2019)

LIST OF FIGURES

  • FIGURE 1 DRUG DISCOVERY SERVICES MARKET SEGMENTATION
  • FIGURE 2 RESEARCH DESIGN
  • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 4 BOTTOM-UP APPROACH
  • FIGURE 5 TOP-DOWN APPROACH
  • FIGURE 6 DATA TRIANGULATION METHODOLOGY
  • FIGURE 7 DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2020 VS. 2025 (USD MILLION)
  • FIGURE 8 DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2020 VS. 2025 (USD MILLION)
  • FIGURE 9 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2020 VS. 2025 (USD MILLION)
  • FIGURE 10 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2020 VS. 2025 (USD MILLION)
  • FIGURE 11 DRUG DISCOVERY SERVICES MARKET, BY REGION, 2020 VS. 2025 (USD MILLION)
  • FIGURE 12 INCREASING R&D EXPENDITURE IN THE PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY TO DRIVE MARKET GROWTH
  • FIGURE 13 SMALL-MOLECULE DRUGS TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICAN DRUG DISCOVERY SERVICES MARKET IN 2020
  • FIGURE 14 CHINA TO REGISTER THE HIGHEST GROWTH IN THE DRUG DISCOVERY SERVICES MARKET DURING THE FORECAST PERIOD
  • FIGURE 15 DRUG DISCOVERY SERVICES MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
  • FIGURE 16 R&D SPENDING OF PHRMA MEMBER COMPANIES, 2001-2017 (USD BILLION)
  • FIGURE 17 ACTIVE PHARMACEUTICAL PIPELINE, JANUARY 2009-JANUARY 2019
  • FIGURE 18 NUMBER OF ORPHAN INDICATIONS APPROVED IN THE US (2010-2017)
  • FIGURE 19 NUMBER OF REGISTERED STUDIES (2005-2017)
  • FIGURE 20 AVERAGE COST TO DEVELOP ONE NEW APPROVED DRUG-INCLUDING THE COST OF FAILURES
  • FIGURE 21 R&D PIPELINE, BY THERAPY GROUP, 2018 & 2019
  • FIGURE 22 TOTAL NUMBER OF CLINICAL TRIALS FOR ONCOLOGY, BY REGION (AS OF DECEMBER 2019)
  • FIGURE 23 TOTAL NUMBER OF CLINICAL TRIALS: GLOBAL VS. NORTH AMERICA
  • FIGURE 24 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET SNAPSHOT
  • FIGURE 25 US: PIPELINE SPLIT OF PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY PHASE (JANUARY 2019)
  • FIGURE 26 UK: PHARMACEUTICAL R&D EXPENDITURE, 2013-2017
  • FIGURE 27 SPAIN: PHARMACEUTICAL R&D EXPENDITURE, 2011-2017
  • FIGURE 28 APAC: DRUG DISCOVERY SERVICES MARKET SNAPSHOT
  • FIGURE 29 DRUG DISCOVERY SERVICES MARKET SHARE (2018)
  • FIGURE 30 GLOBAL DRUG DISCOVERY SERVICES MARKET: COMPETITIVE LEADERSHIP MAPPING (2018) 122  
  • FIGURE 31 LABCORP: COMPANY SNAPSHOT (2018)
  • FIGURE 32 EUROFINS SCIENTIFIC SE: COMPANY SNAPSHOT (2018)
  • FIGURE 33 CHARLES RIVER LABORATORIES INTERNATIONAL: COMPANY SNAPSHOT (2018)
  • FIGURE 34 EVOTEC SE: COMPANY SNAPSHOT (2018)
  • FIGURE 35 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2018)
  • FIGURE 36 SYNGENE: COMPANY SNAPSHOT (2018)
  • FIGURE 37 JUBILANT LIFESCIENCES: COMPANY SNAPSHOT (2018)
  • FIGURE 38 GENSCRIPT BIOTECH CORPORATION: COMPANY SNAPSHOT (2018)
  • FIGURE 39 PIRAMAL ENTERPRISES LIMITED: COMPANY SNAPSHOT (2018)
目次
Product Code: PH 5682

"Drug discovery services market to register a CAGR of 12.1% from 2020 to 2025."

The global drug discovery services market is projected to reach USD 19.1 billion by 2025 from USD 10.7 billion in 2020, at a CAGR of 12.1% from 2020 to 2025. The growth of the industry is driven primarily by factors such as growing R&D expenditure in the pharmaceutical & biopharmaceutical industry, increasing demand for outsourcing analytical testing and clinical trial services, initiatives for research on rare diseases and orphan drugs, and focus on drug discovery. Growth in the biologics market and patent expiries will further provide opportunities in the drug discovery services industry. Developing economies are expected to offer a wide range of growth opportunities for players in the market.

"The Hit-to-Lead process segment is anticipated to grow at the fastest growth rate during the forecast period."

Based on the process, the drug discovery services market is segmented into target selection, target validation, hit-to-lead identification, lead optimization, and candidate validation. Hit-to-lead identification process is anticipated to be the fastest-growing segment due to the high outsourcing of these services to CROs by the pharmaceutical companies and the emerging advanced technologies for high-throughput screening (HTS) and H2L as well as reductions in development time.

"Medicinal Chemistry segment is estimated to account for the largest share of the drug discovery services market in 2020."

Based on type, the drug discovery services market is segmented into medicinal chemistry services, biology services, and drug metabolism and pharmacokinetics (DMPK). The medicinal chemistry services segment is estimated to account for the largest share of the drug discovery services market due to the widespread application of medicinal chemistry in various phases of preclinical drug discovery to deliver robust candidates.

"Oncology segment is anticipated to grow at the fastest growth rate during the forecast period."

Based on the therapeutic area, the drug discovery services market is segmented into oncology, cardiovascular diseases, neurology, infectious and immune system diseases, digestive system diseases, and other therapeutic areas. Of all these therapeutic segments, oncology will grow at the fastest CAGR in the drug discovery services market in 2019. The high growth of the oncology segment can be attributed to factors such as the increasing number of patients who have cancer, the subsequent increase in the demand for cancer therapies and the growing R&D expenditure by pharmaceutical companies in this therapeutic area.

"North America is expected to dominate the drug discovery services market in 2020."

North America, which includes the US and Canada, is estimated to account for the largest share of the drug discovery services market. The large share of this region can primarily be attributed to the presence of well-established CROs; rising R&D expenditure by pharmaceutical & biopharmaceutical companies and the availability of latest techniques, instruments, and facilities for drug discovery research are driving the growth of this region.

Breakdown of supply-side primary interviews, by company type, designation, and region:

  • By Company Type: Tier 1 (40%) , Tier 2 (30%), and Tier 3 (30%)
  • By Designation: C-level (27%), Director-level (18%), and Others (55%)
  • By Region: North America (50%), Europe (20%), Asia Pacific (20%), and RoW (10%)

The key players operating in this market include: Thermo Fisher Scientific, Inc. (US), Albany Molecular Research, Inc. (US), Charles River Laboratories International, Inc. (US), Evotec SE (Germany), Eurofins Scientific (Luxembourg), WuXi AppTec (China), GenScript Biotech Corporation (China), Jubilant Life Sciences (India), Laboratory Corporation of America Holdings (US), Piramal Enterprises Ltd. (India), Viva Biotech (China), Domainex (UK), Shanghai Medicilon, Inc. (China), TCG Lifesciences Pvt. Limited (India), Frontage Holdings (US), Pharmaceutical Product Development, LLC (US), Syngene International Ltd. (India), ChemPartner Co., Ltd (China), Aurigene Discovery Technologies Limited (A subsidiary of Dr. Reddy's, Laboratories) (India), and Selvita S.A. (Poland). Services launches, expansions, collaborations, agreements, partnerships and acquisitions are the key growth strategies followed by most players in this market.

Research Coverage:

This report studies the drug discovery services market based on the process, type, drug type, therapeutic area, company type, and region. The report also analyzes factors (such as drivers, restraints, opportunities, and trends) affecting market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro-markets concerning their growth trends, prospects, and contributions to the total drug discovery services market. The report forecasts the revenue of the market segments concerning four major regions.

Reasons to Buy the Report:

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the drug discovery services offered by the key 20 players in the drug discovery services market. The report analyzes the drug discovery services market by process, type, drug type, therapeutic area, company type, and region.
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various drug discovery services, their adoption, type of applications across key geographic regions.
  • Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the drug discovery services market
  • Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the drug discovery services market along with a competitive leadership mapping of up to 25 players in the market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED FOR THE STUDY
  • 1.4 CURRENCY
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
    • 2.2.2 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
    • 2.2.3 GROWTH FORECAST
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.4 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 DRUG DISCOVERY SERVICES MARKET OVERVIEW
  • 4.2 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE & COUNTRY (2020)
  • 4.3 DRUG DISCOVERY SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Growing R&D expenditure in the pharmaceutical & biopharmaceutical industry
      • 5.2.1.2 Increasing demand for outsourcing analytical testing and clinical trial services
      • 5.2.1.3 Initiatives for research on rare diseases and orphan drugs
      • 5.2.1.4 Focus on drug discovery
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High cost of drug discovery and development
      • 5.2.2.2 Stringent regulations governing drug discovery and animal usage
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Growth in the biologics market
      • 5.2.3.2 Patent expiries
      • 5.2.3.3 Emerging markets
    • 5.2.4 TRENDS
      • 5.2.4.1 Growing adoption of artificial intelligence-based tools for drug discovery

6 DRUG DISCOVERY SERVICES MARKET, BY PROCESS

  • 6.1 INTRODUCTION
  • 6.2 TARGET SELECTION
    • 6.2.1 INCREASING DEMAND FOR PERSONALIZED MEDICINE TO SUPPORT THE GROWTH OF THIS MARKET
  • 6.3 TARGET VALIDATION
    • 6.3.1 RISING NUMBER OF DRUG DISCOVERY RESEARCH ACTIVITIES TO SUPPORT MARKET GROWTH
  • 6.4 HIT-TO-LEAD IDENTIFICATION
    • 6.4.1 HIT-TO-LEAD IDENTIFICATION IS THE LARGEST PROCESS SEGMENT IN THE MARKET
  • 6.5 LEAD OPTIMIZATION
    • 6.5.1 LEAD OPTIMIZATION REQUIRES STATE-OF-THE-ART INFORMATICS SYSTEMS TO FACILITATE TRANSPARENT PRESENTATION AND ANALYSIS
  • 6.6 CANDIDATE VALIDATION
    • 6.6.1 CANDIDATE VALIDATION SEGMENT TO GROW AT A HIGH CAGR DURING THE FORECAST PERIOD

7 DRUG DISCOVERY SERVICES MARKET, BY TYPE

  • 7.1 INTRODUCTION
  • 7.2 MEDICINAL CHEMISTRY SERVICES
    • 7.2.1 WIDE APPLICATIONS OF MEDICINAL CHEMISTRY IN DRUG DISCOVERY ARE A MAJOR FACTOR DRIVING MARKET GROWTH
  • 7.3 BIOLOGY SERVICES
    • 7.3.1 RESTRICTIONS ON THE USAGE OF ANIMALS IN RESEARCH ACTIVITIES MAY LIMIT MARKET GROWTH
  • 7.4 DRUG METABOLISM & PHARMACOKINETICS
    • 7.4.1 DMPK STUDIES ARE EMPLOYED AT THE DISCOVERY, CANDIDATE SELECTION, INVESTIGATIONAL NEW DRUG, AND NEW DRUG APPLICATION STAGES

8 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE

  • 8.1 INTRODUCTION
  • 8.2 SMALL-MOLECULE DRUGS
    • 8.2.1 INCREASING NUMBER OF START-UPS AND NEW ENTRANTS IN THE SMALL-MOLECULE DRUGS SEGMENT WILL DRIVE THE GROWTH OF THIS MARKET DURING THE FORECAST PERIOD
  • 8.3 BIOLOGIC DRUGS
    • 8.3.1 HIGH SET-UP COSTS OF THE INSTRUMENTS REQUIRED FOR BIOLOGIC DRUG MANUFACTURING MAY LIMIT MARKET GROWTH TO A CERTAIN EXTENT

9 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA

  • 9.1 INTRODUCTION
  • 9.2 ONCOLOGY
    • 9.2.1 HIGH AND GROWING NUMBER OF RESEARCH STUDIES ON CANCER THERAPEUTICS TO SUPPORT MARKET GROWTH
  • 9.3 NEUROLOGY
    • 9.3.1 INCREASING NUMBER OF PATIENTS SUFFERING FROM NEUROLOGICAL DISORDERS IS DRIVING MARKET GROWTH
  • 9.4 INFECTIOUS AND IMMUNE SYSTEM DISEASES
    • 9.4.1 EMERGENCE OF NEW INFECTIOUS DISEASES TO DRIVE MARKET GROWTH
  • 9.5 DIGESTIVE SYSTEM DISEASES
    • 9.5.1 AS THERE IS A HUGE POPULATION SEEKING EFFECTIVE REMEDIES FOR DIGESTIVE DISEASES, PHARMACEUTICAL COMPANIES ARE INVESTING SIGNIFICANTLY IN R&D FOR THE DEVELOPMENT OF INNOVATIVE DRUGS
  • 9.6 CARDIOVASCULAR DISEASES
    • 9.6.1 HIGH GLOBAL BURDEN OF CARDIOVASCULAR DISEASES HAS INCREASED THE FOCUS ON DEVELOPING EFFECTIVE DRUGS
  • 9.7 OTHER THERAPEUTIC AREAS

10 DRUG DISCOVERY SERVICES MARKET, BY COMPANY TYPE

  • 10.1 INTRODUCTION
  • 10.2 TIER 1 PHARMACEUTICAL COMPANIES
  • 10.3 TIER 2 PHARMACEUTICAL COMPANIES
  • 10.4 TIER 3 PHARMACEUTICAL COMPANIES

11 DRUG DISCOVERY SERVICES MARKET, BY REGION

  • 11.1 INTRODUCTION
  • 11.2 NORTH AMERICA
    • 11.2.1 US
      • 11.2.1.1 Availability of advanced R&D infrastructure has driven the growth of the US market
    • 11.2.2 CANADA
      • 11.2.2.1 Preference of pharmaceutical companies to conduct clinical trials in Canada to support market growth
  • 11.3 EUROPE
    • 11.3.1 GERMANY
      • 11.3.1.1 Government support and flexible labor laws are driving the growth of the German drug discovery services market
    • 11.3.2 UK
      • 11.3.2.1 Investment by pharmaceutical sponsors in the UK for drug discovery services to support market growth
    • 11.3.3 FRANCE
      • 11.3.3.1 High number of oncology clinical trials in France to drive market growth
    • 11.3.4 ITALY
      • 11.3.4.1 High number of clinical trials and the low drug approval time are the major factors driving market growth
    • 11.3.5 SPAIN
      • 11.3.5.1 Short study start-up times and rising R&D expenditure to boost the growth of the Spanish market
    • 11.3.6 REST OF EUROPE
  • 11.4 ASIA PACIFIC
    • 11.4.1 CHINA
      • 11.4.1.1 Low cost of clinical trials and large pharmaceutical R&D footprint in China to drive market growth
    • 11.4.2 INDIA
      • 11.4.2.1 Low-cost services and availability of skilled workforce to support market growth in India
    • 11.4.3 JAPAN
      • 11.4.3.1 Government initiatives for drug innovation to support market growth in Japan
    • 11.4.4 REST OF ASIA PACIFIC
  • 11.5 REST OF THE WORLD

12 COMPETITIVE LANDSCAPE

  • 12.1 OVERVIEW
  • 12.2 MARKET SHARE ANALYSIS
  • 12.3 COMPETITIVE SCENARIO
    • 12.3.1 PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS
    • 12.3.2 SERVICE LAUNCHES
    • 12.3.3 MERGERS & ACQUISITIONS
    • 12.3.4 EXPANSIONS
  • 12.4 COMPETITIVE LEADERSHIP MAPPING
    • 12.4.1 VISIONARY LEADERS
    • 12.4.2 INNOVATORS
    • 12.4.3 DYNAMIC DIFFERENTIATORS
    • 12.4.4 EMERGING COMPANIES

13 COMPANY PROFILES

(Business overview, Services offered, Recent developments, MNM view)*

  • 13.1 LABORATORY CORPORATION OF AMERICA HOLDINGS
  • 13.2 EUROFINS SCIENTIFIC SE
  • 13.3 CHARLES RIVER LABORATORIES INTERNATIONAL
  • 13.4 EVOTEC SE
  • 13.5 THERMO FISHER SCIENTIFIC
  • 13.6 ALBANY MOLECULAR RESEARCH, INC.
  • 13.7 SYNGENE INTERNATIONAL LIMITED
  • 13.8 JUBILANT LIFESCIENCES
  • 13.9 GENSCRIPT BIOTECH CORPORATION
  • 13.10 PIRAMAL ENTERPRISES LIMITED
  • 13.11 SELVITA S.A.
  • 13.12 AURIGENE DISCOVERY TECHNOLOGIES (A SUBSIDIARY OF DR. REDDY'S LABORATORIES)
  • 13.13 DOMAINEX LTD.
  • 13.14 WUXI APPTEC
  • 13.15 CHEMPARTNER CO., LTD.
  • 13.16 FRONTAGE HOLDINGS
  • 13.17 PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC
  • 13.18 SHANGHAI MEDICILON, INC.
  • 13.19 TCG LIFESCIENCES PVT. LIMITED
  • 13.20 VIVA BIOTECH (SHANGHAI) LTD.

Business overview, Services offered, Recent developments, MNM view might not be captured in case of unlisted companies.

14 APPENDIX

  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.3 AVAILABLE CUSTOMIZATIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS